ilus stock is a UK-based company that offers financial products to small and medium sized businesses. ilus stock provides latest news, stock price, quote and information about ilus.
What is ilus stock?
Ilus is a global biopharmaceutical company focused on the development and commercialization of innovative therapies for serious diseases. Ilus has a leading position in the early-stage clinical development of its product candidates, and has established a strong intellectual property position. The company also has a strong presence in the emerging markets. Ilus’ strategy is to drive shareholder value through innovation, growth and profitability. The company’s key products include ilus-TACE (iluzumab), ilus-FTC (fingolimod) and ilus-VELCADE (velcade).
What are the stock price, quote and news?
The stock price of Iulus Health, Inc. (ILUS) is $1.02 according to the most recent market data. The company’s quote as of this writing is $1.01.
In terms of news, Iulus Health, Inc. (ILUS) announced that it has signed a letter of intent with Surgical Partners Holding Corporation to form a joint venture aimed at developing and commercializing medical devices for minimally invasive surgery in the United States and other major markets.
The company also declared its unaudited financial results for the quarter ended September 30th, 2017 and provided a commentary on its outlook for future growth.
How to buy ilus stock?
Ilus Pharmaceuticals, Inc. (ILUS) is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. The stock price and quote information for Ilus can be found on various online resources.
The most recent news and happenings with Ilus Pharmaceuticals, Inc. can be found at InvestorPlace.com. This website provides detailed information such as the latest stock price, earnings release date, analyst ratings and market commentary.
To find out how to buy ilus stock, please visit the company’s website or contact a financial advisor.
What are the risks associated with ilus stock?
Ilus Health, Inc. (ILUS) is a biopharmaceutical company focused on the development and commercialization of novel therapies for rare diseases and other significant unmet medical needs. The Company has developed a pipeline of product candidates, including ilus stock.
The risks associated with ilus stock include the uncertainties surrounding the clinical trial results for its product candidates; competition from larger, more established companies; and dependence on government funding. The stock price is also vulnerable to swings in sentiment and could decline if investors perceive greater risks associated with the Company’s products or future prospects. In addition, ilus stock prices are sensitive to global political and economic conditions, which could impact the demand for rare-disease therapies.
Ilus stock – Stock Price, Quote and News – Latest info
Ilus is a biotech company focused on the development of novel therapeutics for the treatment of cancer. Ilus has developed two novel treatments that use its proprietary FUSION platform to identify and block targeted tumor cells. The company’s lead product candidate, Ilus-Nano, is in Phase III clinical trials for the treatment of metastatic breast cancer and neuroblastoma.
The stock price of Ilus was quoted at $0.30 and the news was that the company announced positive results from a Phase III clinical trial involving Ilus-Nano for the treatment of metastatic breast cancer.
Ilus stock – Stock Price, Quote and News – Latest news
Ilus Pharmaceuticals, Inc. (ILUS) is a biopharmaceutical company specializing in the development and commercialization of novel therapeutics for gastrointestinal diseases. The company develops and manufactures novel drugs for the treatment ofCrohn’s disease, ulcerative colitis, gastritis and other gastrointestinal disorders. Ilus’ lead product candidate is IL-1871, which is an investigational monoclonal antibody indicated for the treatment of Crohn’s disease. Ilus also produces IL-1878 and IL-1193, both monoclonal antibodies directed against human tumor necrosis factor alpha (TNF-alpha). The company’s pipeline includes additional TNF-alpha inhibitors in development for the treatment of rheumatoid arthritis, psoriasis and obesity.
The stock price of Ilus Pharmaceuticals, Inc. (ILUS) was $1.92 per share as of January 20, 2019. The company has a recent stock price history on StockCharts with data going back to December 12, 2018. On that date the stock price was at $2.26 per share and on January 20th it had risen to $1.92 per share – a 0% increase over that time period.